Acta Scientific Pharmacology

Case Report Volume 1 Issue 8

A Case Report On Potentially Fatal Condition-Bullous Pemphigoid

K Mounika* and EAlekhya Goud

Department of Pharmacy Practice, Santhiram College of Pharmacy, Nandyal, Kurnool, Andhra Pradesh, India

*Corresponding Author: K Mounika, Department of Pharmacy Practice, Santhiram College of Pharmacy, Nandyal, Kurnool, Andhra Pradesh, India.

Received: June 27, 2020; Published: July 30, 2020

×

Abstract

 Bullous pemphigoid is a rare autoimmune disease which involves blisters formation betweenskin layers. It occurs due to production of autoantibodies against hemidesmosomal autoantigens BPAG1 and BPAG2. It mainly affects skin but rarely mouth, eye and genitals are also affected. The formation of blisters on the skin takes place due to malfunction in the immune system. The symptoms include severe itching, or erythematous skin with urticated and infiltrated plaques that are annular pattern. It is usually diagnosed by clinical, histopathological and immunological tests. The first line treatment is corticosteroids and the other treatment options are Immunosuppressant’s and certain antibiotics to decrease infection. A 64 years male patient admitted with C/O fluid filled lesions over hands and legs since 6 days. On cutaneous examination, patient has multiple tense dome shaped bullae of size ranging from 1 × 1cms to 2 × 3cms over flexor aspects of both upper limbs.Multiple wheals of size ranging from 1 × 1cms to 4 × 5cms present over dorsum of both hands, upper back and lateral aspects of both arms. On Histological examination, infiltration of eosinophils and lymphocytes were seen in upper dermis and bulla. Patient showed negative to Nikolsky sign and bulla spread sign. Patient was treated with Inj.Decadron OD, Tab.Taxim BD, Inj. Avil OD, Tab.Rantac BD, Tab.Fourts B OD, Fucibet cream BD, Tab. Bepozic OD.

Keywords: Bullous Pemphigoid;Autoimmune; Hemidesmosomal; Blisters; Nikolsky sign

×

References

  1. Zillikens D., et al. “An autoimmune blistering disorders of the elderly”.Journal of Geriatric Dermatology4 (2016): 35-41.
  2. Michael Kasperkewicz., et al. “Pemphigoid diseases: Pathogenesis, diagnosis and treatment”. Autoimmunity1 (2012): 55-70.
  3. Lo Schiavo A., et al. “Bullous pemphigoid etiology, pathogenesis and inducing factors: facts and controversies”.Clinical Dermatology31 (2013): 391-399.
  4. Jorge Parellada., et al. “A case on Bullous pemphigoid: A prevalent and potentially fatal condition”.Cureus4 (2018): 1-7.
  5. Fuertes de Vega I., et al. “Bullous pemphigoid clinical practice guidelines”.ActasDermosifiliogrficas 105 (2014): 328-446.
  6. Schmidt E andZillikens D. “Modern diagnosis of Autoimmune blistering skin diseases”.Autoimmune Review10 (2010): 84-89.
  7. Cortes B., et al. “Mortality of Bullous pemphigoid in Switzerland: a prospective study”.British Journal of Dermatology165 (2011): 368-374.
  8. Joly P., et al. “Incidence and mortality of Bullous pemphigoid in France”.Journal Investigation on Dermatology 132 (2012): 1998-2004.
  9. Ujiie H., et al. “What’s new in Bullous pemphigoid”.Journal of Dermatology37 (2010): 3194-204.
  10. Cozzani E., et al. “Atypicalpresentations of Bullos pemphigoid:Clinical and immunopathological aspects”.Autoimmune Review14 (2015): 438-445.
  11. Michael Hertl. Autoimmune diseases of the skin:Pathogenesis, diagnosis and management, second revised and enlarged edition(2005): 84-95.
  12. Viallant L., et al. “Evaluation of clinical criteria for diagnosis of Bullous pemphigoid”.Archives ofDermatology134 (1998): 1075-1080.
  13. Mehta V and Balachandran C.“Localized flexural Bullous pemphigoid”.Indian Journal of Dermatology53 (2008): 157-158.
  14. Ludwig RJ., et al. “Emerging treatments of Bullous pemphigoid diseases”.Trends in Molecular Medicine 19 (2013): 501-512.
  15. Yeh SW., et al. “Blistering disorders: Diagnosis and treatment”. Dermatology Therapy16 (2003): 214-223.
×

Citation

Citation: K Mounika and EAlekhya Goud. “A Case Report On Potentially Fatal Condition-Bullous Pemphigoid". Acta Scientific Pharmacology 1.8 (2020): 24-27.




Metrics

Acceptance rate36%
Acceptance to publication20-30 days

Indexed In


News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US